[email protected]
Mike Curtis, PhD, is the President and Chief Executive Officer at eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure. In this role, he is responsible for managing the development of eGenesis’ xenotransplantation programs. In 2024, Dr. Curtis landed on the TIME100 Health list for eGenesis' pioneering technology that enabled a pig kidney to be transplanted into a human.
Dr. Curtis has more than 25 years of experience in scientific research and leadership in biopharmaceutical drug development across multiple therapeutic areas. Before joining eGenesis, he served as President and Head of R&D at Cadent Therapeutics, where he oversaw R&D, regulatory and intellectual property operations. During his tenure at Cadent, the company developed a pipeline of novel therapies for the treatment of psychiatric and movement disorders leading to its acquisition by Novartis at the end of 2020.
Prior to Cadent, Dr. Curtis was responsible for product development and regulatory affairs at Catabasis Pharmaceuticals, where he led the clinical advancement of three products from discovery through first-in-human and Phase 2 studies. His first executive role was at the oncology company Infinity Pharmaceuticals, where he established and led a 30-scientist team that was responsible for all product development activities including the advancement of the lead candidates into Phase 3 clinical trials.
Dr. Curtis holds an A.Sc. in biotechnology from Cobleskill College and a B.Sc. in biochemistry from the College of Environmental Science and Forestry. He earned his doctorate in cell and molecular biology from the State University of New York Upstate Medical University.
Related Speakers View all
Hanneke Schuitemaker
Virologist, Global Head of Viral Vaccine Discovery &...
|
|
Hasini Jayatilaka
Postdoctoral Researcher at Stanford University
|
|
Reshma Kewalramani
CEO & President at Vertex Pharmaceuticals
|
|
Thomas J Bartosh, PhD
Assistant Professor, Texas A&M University Health Sci...
|
|
Inmaculada Hernandez
Pharmaceutical Health Services Researcher & Accessib...
|
|
John Brownstein
Chief Innovation Officer, Boston Children’s Hospital...
|
|
Dr. Lloyd Minor
Scientist, Surgeon & Academic Leader & Dean of the S...
|
|
Tania Simoncelli
Vice President of Science In Society at Chan Zuckerb...
|
|
Cindy Eckert
Serial Entrepreneur, Founder & CEO of The Pink Ceili...
|
|
Wendy Chung
Physician, Clinical & Molecular Geneticist
|
|
Lisa Cooper
Director at Johns Hopkins Center for Health Equity a...
|
|
Leonard I. Zon
Cancer Genetics & Stem Cell Biology Researcher; Prof...
|
|
Christopher Austin
Senior Vice President of Research Technologies at GS...
|
|
Dr. Joel Selanikio
Award-Winning Physician, Health & Technology Activis...
|
|
Bud Frazier
Director, Cardiovascular Surgery Research, Texas Hea...
|
|
Dr. Francis Collins
Groundbreaking Geneticist; National Institutes of He...
|
|
Susan Lim
Surgical Pioneer in Singapore; CEO of Centre for Rob...
|
|
Edward M. Schaeffer, M.D., Ph.D.
Internationally Recognized Urologist & Prostate Canc...
|
|
Chris Moxham
Founder & CEO at Transcripta Bio
|
|
Zain Kassam
Chief Medical Officer at Seed Health
|